State Street Corp Purchases 256,029 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM)

State Street Corp boosted its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 433.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 315,036 shares of the company’s stock after acquiring an additional 256,029 shares during the period. State Street Corp’s holdings in Eliem Therapeutics were worth $1,604,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ELYM. Rhumbline Advisers acquired a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at about $59,000. SG Americas Securities LLC acquired a new position in Eliem Therapeutics during the 3rd quarter worth approximately $60,000. Valence8 US LP bought a new position in shares of Eliem Therapeutics during the 3rd quarter worth approximately $61,000. Dimensional Fund Advisors LP acquired a new stake in shares of Eliem Therapeutics in the second quarter valued at approximately $89,000. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Eliem Therapeutics in the third quarter worth $81,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Eliem Therapeutics Price Performance

Shares of NASDAQ:ELYM opened at $1.80 on Thursday. The stock has a market capitalization of $53.55 million, a PE ratio of -3.40 and a beta of -0.39. The company’s 50-day moving average price is $3.17 and its two-hundred day moving average price is $5.51. Eliem Therapeutics, Inc. has a one year low of $2.35 and a one year high of $11.55.

Eliem Therapeutics Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.